Literature DB >> 7543624

Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis.

T Lehto1, E Honkanen, A M Teppo, S Meri.   

Abstract

Protectin (CD59) is a low molecular weight glycophosphoinositol-anchored inhibitor of the membrane attack complex of complement (MAC) that is present, for example, on the membranes of endothelial cells and on epithelial cells of glomeruli and distal tubuli. To examine for the possibility that CD59 becomes detached from cell surfaces following cell injury, this study evaluated renal excretion of CD59 in patients with idiopathic membranous glomerulonephritis (MGN; N = 21), diabetic nephropathy (DNP; N = 15) and in healthy control subjects (N = 13). CD59 in human urine was quantitated by a competitive solid-phase radioimmunoassay having approximately 13 kDa soluble urinary CD59 as a standard. Immunofluorescence microscopy demonstrated a decreased expression of CD59 in the glomeruli of MGN patients. Using a Triton X-114 phase separation method 91 to 97% of urinary CD59 was found to be in a soluble form without anchor-associated phospholipid. The mean (+/- SEM) level of urinary CD59 was 5.6 +/- 0.2 micrograms/ml in MGN patients, 3.7 +/- 0.4 micrograms/ml in healthy controls (P < 0.001) and 2.6 +/- 0.1 in DNP patients (P < 0.001). When related to urinary creatinine (UCr) the corresponding values were 11.9 +/- 5.6, 4.8 +/- 0.3 (P = 0.021) and 4.4 +/- 0.2 (P < 0.002), respectively. The amount of CD59 in urine correlated with the urinary excretion of soluble terminal complement complexes, SC5b-9 (r = 0.594, P < 0.006) in MGN patients. The excretion of CD59 also correlated with the excretion of the inflammatory mediator IL-1 beta (r = 0.671, P = 0.001) but not with TNF-alpha (r = 0.314, P = 0.178). No correlation of CD59 excretion was observed with duration of the disease level of proteinuria, serum albumin concentration or serum creatinine level. Based on these findings we speculate that the increased excretion of CD59 into urine in MGN patients is due to complement activation and inflammation induced shedding of CD59 from glomerular cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543624     DOI: 10.1038/ki.1995.197

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  17 in total

1.  Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

2.  Molecular basis for a link between complement and the vascular complications of diabetes.

Authors:  J Acosta; J Hettinga; R Flückiger; N Krumrei; A Goldfine; L Angarita; J Halperin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

3.  Cytolytic complement activity in otitis media with effusion.

Authors:  M Närkiö-Mäkelä; S Meri
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

Review 4.  Role of complement and complement regulatory proteins in the complications of diabetes.

Authors:  Pamela Ghosh; Rupam Sahoo; Anand Vaidya; Michael Chorev; Jose A Halperin
Journal:  Endocr Rev       Date:  2015-04-10       Impact factor: 19.871

5.  Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis.

Authors:  S Meri; T Lehto; C W Sutton; J Tyynelä; M Baumann
Journal:  Biochem J       Date:  1996-06-15       Impact factor: 3.857

6.  Terminal complement complex formation is associated with intervertebral disc degeneration.

Authors:  Graciosa Q Teixeira; Zhiyao Yong; Raquel M Goncalves; Amelie Kuhn; Jana Riegger; Helena Brisby; Helena Barreto Henriksson; Michael Ruf; Andreas Nerlich; Uwe M Mauer; Anita Ignatius; Rolf E Brenner; Cornelia Neidlinger-Wilke
Journal:  Eur Spine J       Date:  2020-09-16       Impact factor: 3.134

7.  Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin.

Authors:  Siti S Abdullah-Soheimi; Boon-Kiong Lim; Onn H Hashim; Adawiyah S Shuib
Journal:  Proteome Sci       Date:  2010-11-17       Impact factor: 2.480

8.  Shedding and enrichment of the glycolipid-anchored complement lysis inhibitor protectin (CD59) into milk fat globules.

Authors:  J Hakulinen; S Meri
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

9.  Soluble CD59 in peritoneal dialysis: a potential biomarker for peritoneal membrane function.

Authors:  Bernardo Faria; Mariana Gaya da Costa; Carla Lima; Loek Willems; Ricardo Brandwijk; Stefan P Berger; Mohamed R Daha; Manuel Pestana; Marc A Seelen; Felix Poppelaars
Journal:  J Nephrol       Date:  2020-12-11       Impact factor: 3.902

10.  Successful treatment of refractory adult Still's disease and membranous glomerulonephritis with infliximab.

Authors:  Taner Babacan; Ahmet Mesut Onat; Yavuz Pehlivan; Gazi Comez; Metin Karakök
Journal:  Clin Rheumatol       Date:  2010-01-26       Impact factor: 3.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.